Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Katie Newlin, RN, MSN, AGPCNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Exploring the Treatment Gap in High-Risk HR+, HER2- Early Breast Cancer (EBC): Eligible Patients Not Receiving Abemaciclib in the US

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

Intravenous Cancer Treatment Education

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Real-world Risk of Recurrence by Nodal Status in Patients with HR+, HER2-, Node-positive, High-Risk Early Breast Cancer

Frontiers in Oncology

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

Clinical Breast Cancer

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Breast Cancer Research Foundation

A revolution in breast cancer prevention is underway—With AI mammogram-based risk assessment starting at 35

U.S. Food and Drug Administration

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

npj Breast Cancer

Imlunestrant with or without abemaciclib in advanced breast cancer: Safety analyses from the EMBER-3 trial

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

Cancers

Body mass index and outcomes in HR+/HER2- metastatic breast cancer treated with palbociclib: Insights from a national real-world study

ESMO Open

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III EMBER-3 trial

Lancet Regional Health

Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy

Annals of Oncology

Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial

HR+ HER2- Breast Cancer Resource Center

Interview with Amy E. Cyr, MD, FACS: Personalization of Management for High-Risk Women